CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today that Dr. Hoyoung Huh, President and CEO of BiPar Sciences, Inc., was appointed Epizyme’s Chairman of the Board of Directors. Epizyme recently announced the closing of a $32M Series B financing led by Bay City Capital (BCC).
